Detalhe da pesquisa
1.
Inefficient CAR-proximal signaling blunts antigen sensitivity.
Nat Immunol
; 21(8): 848-856, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32632291
2.
BATF3 programs CD8+ T cell memory.
Nat Immunol
; 21(11): 1397-1407, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32989328
3.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38084760
4.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
Inglês
| MEDLINE | ID: mdl-37272512
5.
CAR T-cell therapy in multiple myeloma: mission accomplished?
Blood
; 143(4): 305-310, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38033289
6.
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Blood
; 143(8): 685-696, 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37976456
7.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38697166
8.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Br J Haematol
; 2024 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38719214
9.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33626253
10.
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Blood
; 139(1): 87-103, 2022 01 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34320176
11.
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study.
Haematologica
; 109(2): 431-443, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646665
12.
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
Haematologica
; 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38572568
13.
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Haematologica
; 2024 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38654660
14.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Eur J Nucl Med Mol Imaging
; 51(3): 749-755, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37943339
15.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37269857
16.
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Blood
; 138(19): 1830-1842, 2021 11 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34289026
17.
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Blood
; 138(18): 1721-1726, 2021 11 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34115836
18.
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Haematologica
; 108(4): 958-968, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36263838
19.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36546453
20.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the ß2 and ß1 subunits of the proteasome complex.
Haematologica
; 108(6): 1628-1639, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36727403